Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma

Geeta Godara, Grant W. Cannon, Glenn M. Cannon, Robert Bies, Joel B. Nelson, Beth Pflug

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND. Mitogenic and anti-apoptotic actions of endothelin-1 (ET-1) are mediated through endothelin A (ETA) receptors. We investigated endothelin receptor expression in increasingly aggressive phenotype and in vivo effects of combination therapy using ETA antagonist with paclitaxel. METHODS. Dunning prostate cancer cells ranged in aggressiveness from non-tumorigenic G, to tumorigenic, non-metastatic AT-1, and to tumorigenic and metastatic MLL. Binding assays were performed alongside Q-PCR to assess receptor density. MLL xenografts were treated with vehicle, atrasentan, paclitaxel, and paclitaxel+atrasentan. RESULTS. Saturation binding assays demonstrated endothelin receptor density of MLL and AT-1 cells seven- and threefold higher than G cells, respectively. Q-PCR showed 9- and 4.5-fold greater ETA mRNA expression in MLL and AT-1 than G cells, respectively and no endothelin receptor B (ETB) expression. Combination therapy had significant effect on reduction of tumor volume than paclitaxel or atrasentan alone. CONCLUSIONS. ETA expression increases in aggressive prostate carcinoma. ETA blockade combined with paclitaxel may reduce tumor growth in advanced prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalProstate
Volume65
Issue number1
DOIs
StatePublished - Sep 15 2005
Externally publishedYes

Fingerprint

Endothelins
Paclitaxel
Prostate
Adenocarcinoma
Phenotype
Endothelin Receptors
Gastrin-Secreting Cells
Endothelin B Receptors
Carcinoma
Endothelin A Receptors
Polymerase Chain Reaction
Endothelin-1
Tumor Burden
Heterografts
Prostatic Neoplasms
Messenger RNA
Therapeutics
Growth
atrasentan
Neoplasms

Keywords

  • Atrasentan
  • Endothelin receptor A (ET)
  • Endothelin receptor B (ET)
  • Endothelin-1
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. / Godara, Geeta; Cannon, Grant W.; Cannon, Glenn M.; Bies, Robert; Nelson, Joel B.; Pflug, Beth.

In: Prostate, Vol. 65, No. 1, 15.09.2005, p. 27-34.

Research output: Contribution to journalArticle

Godara, Geeta ; Cannon, Grant W. ; Cannon, Glenn M. ; Bies, Robert ; Nelson, Joel B. ; Pflug, Beth. / Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. In: Prostate. 2005 ; Vol. 65, No. 1. pp. 27-34.
@article{f9f3addbf8b14b20be8eb4193033944c,
title = "Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma",
abstract = "BACKGROUND. Mitogenic and anti-apoptotic actions of endothelin-1 (ET-1) are mediated through endothelin A (ETA) receptors. We investigated endothelin receptor expression in increasingly aggressive phenotype and in vivo effects of combination therapy using ETA antagonist with paclitaxel. METHODS. Dunning prostate cancer cells ranged in aggressiveness from non-tumorigenic G, to tumorigenic, non-metastatic AT-1, and to tumorigenic and metastatic MLL. Binding assays were performed alongside Q-PCR to assess receptor density. MLL xenografts were treated with vehicle, atrasentan, paclitaxel, and paclitaxel+atrasentan. RESULTS. Saturation binding assays demonstrated endothelin receptor density of MLL and AT-1 cells seven- and threefold higher than G cells, respectively. Q-PCR showed 9- and 4.5-fold greater ETA mRNA expression in MLL and AT-1 than G cells, respectively and no endothelin receptor B (ETB) expression. Combination therapy had significant effect on reduction of tumor volume than paclitaxel or atrasentan alone. CONCLUSIONS. ETA expression increases in aggressive prostate carcinoma. ETA blockade combined with paclitaxel may reduce tumor growth in advanced prostate carcinoma.",
keywords = "Atrasentan, Endothelin receptor A (ET), Endothelin receptor B (ET), Endothelin-1, Prostate cancer",
author = "Geeta Godara and Cannon, {Grant W.} and Cannon, {Glenn M.} and Robert Bies and Nelson, {Joel B.} and Beth Pflug",
year = "2005",
month = "9",
day = "15",
doi = "10.1002/pros.20252",
language = "English (US)",
volume = "65",
pages = "27--34",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma

AU - Godara, Geeta

AU - Cannon, Grant W.

AU - Cannon, Glenn M.

AU - Bies, Robert

AU - Nelson, Joel B.

AU - Pflug, Beth

PY - 2005/9/15

Y1 - 2005/9/15

N2 - BACKGROUND. Mitogenic and anti-apoptotic actions of endothelin-1 (ET-1) are mediated through endothelin A (ETA) receptors. We investigated endothelin receptor expression in increasingly aggressive phenotype and in vivo effects of combination therapy using ETA antagonist with paclitaxel. METHODS. Dunning prostate cancer cells ranged in aggressiveness from non-tumorigenic G, to tumorigenic, non-metastatic AT-1, and to tumorigenic and metastatic MLL. Binding assays were performed alongside Q-PCR to assess receptor density. MLL xenografts were treated with vehicle, atrasentan, paclitaxel, and paclitaxel+atrasentan. RESULTS. Saturation binding assays demonstrated endothelin receptor density of MLL and AT-1 cells seven- and threefold higher than G cells, respectively. Q-PCR showed 9- and 4.5-fold greater ETA mRNA expression in MLL and AT-1 than G cells, respectively and no endothelin receptor B (ETB) expression. Combination therapy had significant effect on reduction of tumor volume than paclitaxel or atrasentan alone. CONCLUSIONS. ETA expression increases in aggressive prostate carcinoma. ETA blockade combined with paclitaxel may reduce tumor growth in advanced prostate carcinoma.

AB - BACKGROUND. Mitogenic and anti-apoptotic actions of endothelin-1 (ET-1) are mediated through endothelin A (ETA) receptors. We investigated endothelin receptor expression in increasingly aggressive phenotype and in vivo effects of combination therapy using ETA antagonist with paclitaxel. METHODS. Dunning prostate cancer cells ranged in aggressiveness from non-tumorigenic G, to tumorigenic, non-metastatic AT-1, and to tumorigenic and metastatic MLL. Binding assays were performed alongside Q-PCR to assess receptor density. MLL xenografts were treated with vehicle, atrasentan, paclitaxel, and paclitaxel+atrasentan. RESULTS. Saturation binding assays demonstrated endothelin receptor density of MLL and AT-1 cells seven- and threefold higher than G cells, respectively. Q-PCR showed 9- and 4.5-fold greater ETA mRNA expression in MLL and AT-1 than G cells, respectively and no endothelin receptor B (ETB) expression. Combination therapy had significant effect on reduction of tumor volume than paclitaxel or atrasentan alone. CONCLUSIONS. ETA expression increases in aggressive prostate carcinoma. ETA blockade combined with paclitaxel may reduce tumor growth in advanced prostate carcinoma.

KW - Atrasentan

KW - Endothelin receptor A (ET)

KW - Endothelin receptor B (ET)

KW - Endothelin-1

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=24944494039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944494039&partnerID=8YFLogxK

U2 - 10.1002/pros.20252

DO - 10.1002/pros.20252

M3 - Article

VL - 65

SP - 27

EP - 34

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -